Fermenta Biotech LtdQ2 FY21Pharmaceuticals & Biotechnology

Fermenta Biotech Ltd

Q2 FY21 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 2

→The company aims to grow both topline and margins, targeting a four-digit crore revenue in 4-6 years depending on efficiency of plan implementation (Page 15).
→Expect human vitamin D3 volumes to continue growing, though growth rate may taper post-COVID; animal segment worst phase is likely over, expected to stabilize (Page 12-13).
→Capacity expansions, including 25% additional vitamin D3 capacity (plant IV), expected to be fully commissioned by Q2 FY2022, boosting volumes (Page 13-14).
→New nutritional ingredient products like vitamin K1, premixes, minerals to contribute 30-40% revenue over next 4-5 years, supporting growth and diversification (Page 14).
→CAGR for medium-term revenue growth not precisely stated but implied steady sustainable growth with margin target of ~25% EBITDA (Page 14-15).
→Continued focus on new client acquisition and expanding market share in human vitamin D3, especially in the US (Page 9).

Category 3

→Fermenta Biotech aims to achieve a four-digit crore topline in 4-6 years, focusing on both revenue and margin growth, with an emphasis on improving margins (Page 14).
→The company expects new products and forward/backward integration to grow nutritional ingredients to contribute 30-40% of increased revenues in 4-5 years (Page 14).
→Target EBITDA margin is approximately 25%, despite potential volatility from new products entering the market (Page 14).
→Capex plans of Rs. 150-200 Crores over the next 2-3 years will drive capacity expansions in vitamin D3, minerals, vitamin K1, and premix plants enhancing growth potential (Page 8, 13).
→Human nutrition capacity is near full utilization (~100%), with expansions expected to commission by Q2 FY2022, which should support volume and earnings growth (Page 12, 8).
→Animal nutrition segment is gradually recovering from a depressed market and further price improvements are anticipated (Page 11, 12).
→Business losses and one-time provisions from subsidiaries are expected to reduce, improving consolidated profitability going forward (Page 15, 17).

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Fermenta Biotech Ltd and 1,400+ other companies.

→No specific mention of any current or future fundraising through debt or equity was made in the transcript.
→The company has undertaken significant capex (around Rs.150-200 Crores planned over 2-3 years) funded so far by internal accruals.
→There is mention of managing existing debt, with rental income servicing about Rs.75 Crores of loans comfortably.
→No indications of raising fresh equity or debt capital were discussed during the call.
→Focus appears to be on utilizing internal resources and operational cash flows for expansion and project funding.
→The company is monitoring market conditions and may consider options like monetizing real estate to manage finances, but no formal plans cited.

→The transcript does not explicitly mention the current or expected order book or pending orders for Fermenta Biotech Limited.
→Discussion focuses more on capacity expansion, product launches (such as 25-hydroxy-VD3), and market outlook.
→The company highlights delays due to resource allocation but confirms ongoing efforts to commercialize new products.
→Capacity utilization is near full on the human nutrition side, indicating healthy demand.
→Expansion projects for vitamin D3 capacity are underway with commissioning expected mostly by Q2 FY2022.
→No specific figures or timelines related to order book or pending orders are provided in the transcript.

Yes

→Planned capex of approximately ₹150 to ₹200 Crores over the next 2-3 years.
→Initial ₹50-60 Crores expected to be spent in the current year.
→Investments focused on:
→ - Expansion of Vitamin D3 capacity (additional 22-25% planned).
→ - Setting up new facilities for nutritional ingredients like minerals and Vitamin K1.
→ - Establishment of a premix plant for combining various minerals and vitamins.
→ - Enhancements in fermentation capacities through a new greenfield project in Saykha.
→ - Utilization and expansion in existing plants where feasible.
→Current Vitamin D3 capacity expansion partly commercialized; full commissioning expected by Q2 FY2022.
→Strategic focus on strengthening nutritional ingredient portfolio and value-added vitamin D3 formats.

How does Fermenta Biotech Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Fermenta Biotech Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Fermenta Biotech Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.